Article Text

Download PDFPDF
Original research
Embolization of intra-axial hypervascular tumors with Onyx: report of three cases
  1. Guilherme Dabus1,
  2. Johnny Pryor2,
  3. Gabriela Spilberg3,
  4. Edgar A Samaniego1,
  5. Raul G Nogueira4
  1. 1Department of Neurointerventional Surgery, Baptist Cardiac and Vascular Institute, Miami, Florida, USA
  2. 2Department of Interventional Neuroradiology and Endovascular Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA
  3. 3Department of Radiology, University of Massachusetts, Worcester, Massachusetts, USA
  4. 4Department of Neurology, Emory University, Atlanta, Georgia, USA
  1. Correspondence to Dr R G Nogueira, Department of Neurology, Emory University, Atlanta, GA 30303, USA; raul.g.nogueira{at}


Complete surgical resection of intra-axial hypervascular tumors located in the posterior fossa, in particular hemangioblastomas, may be challenging due to tumor location, mass effect and excessive bleeding. Embolization of these lesions can be done preoperatively or as a palliative measure in patients who are not surgical candidates. Preoperative embolization may reduce intraoperative blood loss, shorten surgical time and increase the chance of a complete resection. However, the safety and effectiveness of this procedure is still a matter of debate. Three cases of intra-axial hypervascular tumors in the posterior fossa (two confirmed hemangioblastomas) that were embolized using a non-adhesive liquid embolic agent (Onyx) are reported.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Correction notice This article has been updated since it was published Online First. The author name Edgar Samaniego has been updated to Edgar A Samaniego.

  • Competing interests GD is a consultant for Codman Neurovascular and a shareholder in Surpass Medical. JP is a proctor/consultant for EV3 Neurovascular. RGN is a proctor/physician on the advisory board for EV3 Neurovascular.

  • Provenance and peer review Not commissioned; externally peer reviewed.